NASDAQ$WVE
Wave Life Sciences Ltd · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Wave Life Sciences reported financial results for Q1 2023 and provided a business update.
Wave Life Sciences reported a net loss of $27.4 million for the first quarter of 2023. The company's cash and cash equivalents totaled $207.6 million as of March 31, 2023, expected to fund operations into 2025.
- Launched transformational collaboration with GSK, expected to build patient and shareholder value.
- Advanced WVE-006 towards CTA submissions for alpha-1 antitrypsin deficiency.
- Prepared for launch of potentially registrational Phase 2 study of WVE-N531 for boys with DMD.
- Presented WVE-N531 clinical data at MDA Conference.
Headline financials
Revenue & EPS history
Wave Life Sciences · Revenue · Quarterly
$12.9M
Forward guidance
Wave Life Sciences anticipates several milestones and events related to their drug development programs and platform in the near future.
Tailwinds
- Initiate dosing in Part B of WVE-N531 potentially registrational Phase 2 clinical trial in 2023
- Deliver data from Part B in 2024 for WVE-N531
- Submit CTAs for first-in-human study in 2H 2023 for WVE-006
- Deliver additional single-dose and multi-dose biomarker and safety clinical data in 2H 2023 for WVE-003
- Advance collaboration activities with GSK, with potential for additional cash inflows in 2023 and beyond
Headwinds
- The update in expected timing for HD single-dose clinical data is due to a publicly announced cyber-attack that took place at Wave’s mHTT assay vendor in April 2023.
- No Wave data or patient samples were impacted by the attack.
- Wave remains in close contact with the vendor as they address this issue.
- The company anticipates virtual investor event to be held in the third quarter of 2023.
- The company will share preclinical data on new wholly-owned programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.9%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+8.2%
Avg return
30 days after
48%
20 / 42 earnings
Positive
+42.4%
Q4 2023
Best reaction
-16.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.4% | +5.3% | -6.9% | |
| Q4 2025 | +5.6% | -7.6% | -56.2% | |
| Q3 2025 | -10.3% | -9.9% | +157.4% | |
| Q1 2025 | +0.5% | -1.5% | +11.2% | |
| Q4 2024 | +11.7% | -6.5% | -33.9% | |
| Q3 2024 | -4.6% | -16.8% | -15.8% | |
| Q2 2024 | -9.5% | -6.9% | -14.2% | |
| Q1 2024 | -3.9% | -0.2% | -0.7% | |
| Q4 2023 | +42.4% | +42.0% | +23.4% | |
| Q3 2023 | -8.9% | -5.6% | -21.7% | |
| Q2 2023 | +14.4% | +3.0% | +3.9% | |
| Q1 2023 | -0.8% | +8.2% | +23.6% | |
| Q4 2022 | -11.1% | -11.8% | +1.9% | |
| Q3 2022 | -7.6% | -19.3% | -1.3% | |
| Q2 2022 | +37.3% | +45.1% | +26.7% | |
| Q1 2022 | -16.3% | -13.6% | +46.3% | |
| Q4 2021 | -5.7% | -17.1% | -17.5% | |
| Q3 2021 | +1.5% | -3.2% | -25.7% | |
| Q2 2021 | +7.0% | -0.4% | +12.3% | |
| Q1 2021 | +1.5% | +9.6% | +18.3% | |
| Q4 2020 | -7.8% | -8.9% | -40.5% | |
| Q3 2020 | +2.8% | +11.9% | +19.3% | |
| Q2 2020 | +1.5% | -0.5% | +36.9% | |
| Q1 2020 | +28.2% | +30.2% | +28.1% | |
| Q4 2019 | -3.2% | +9.8% | +6.6% | |
| Q3 2019 | -1.0% | +3.1% | +20.9% | |
| Q2 2019 | -3.4% | -9.4% | +3.1% | |
| Q1 2019 | -0.8% | -1.0% | -10.7% | |
| Q4 2018 | +6.1% | +7.6% | -7.3% | |
| Q3 2018 | -12.3% | -15.3% | +4.4% | |
| Q2 2018 | +10.7% | +16.4% | +25.7% | |
| Q1 2018 | -6.9% | -9.7% | +11.5% | |
| Q4 2017 | -7.9% | -11.7% | -10.5% | |
| Q3 2017 | +3.2% | +12.0% | +66.5% | |
| Q2 2017 | -7.7% | -12.8% | +18.4% | |
| Q1 2017 | +2.6% | +7.9% | -2.2% | |
| Q4 2016 | -2.0% | -4.4% | -14.8% | |
| Q3 2016 | +15.3% | +18.2% | +5.2% | |
| Q2 2016 | +5.7% | +13.5% | +26.9% | |
| Q1 2016 | -2.7% | — | — | |
| Q4 2015 | -3.1% | — | — | |
| Q3 2015 | +11.1% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro